All Updates

All Updates

icon
Filter
M&A
Click Therapeutics acquires assets of Better Therapeutics for undisclosed sum
Preventive Healthcare
May 22, 2024
This week:
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
Funding
Fraction AI raises USD 6 million in pre-seed funding to scale hybrid data labeling
Machine Learning Infrastructure
Dec 23, 2024
Last week:
Partnerships
Rocket Lab launches sixth Synspective radar satellite as part of ongoing partnership
Space Travel and Exploration Tech
Dec 21, 2024
Partnerships
EHang partners with Changan Automobile to develop eVTOL aircraft for personal transportation
Passenger eVTOL Aircraft
Dec 21, 2024
Preventive Healthcare

Preventive Healthcare

May 22, 2024

Click Therapeutics acquires assets of Better Therapeutics for undisclosed sum

M&A

  • Click Therapeutics, a mental-health-focused digital therapeutics provider, has acquired the assets of cardiometabolic digital therapeutic provider Better Therapeutics for an undisclosed sum. The assets acquired include Better Therapeutics' FDA-authorized prescription digital therapeutic for type 2 diabetes (AspyreRx - BT-001) and other assets related to the treatment of obesity, hypertension, and hyperlipidemia.

  • With the acquisition of Better Therapeutics' assets, Click Therapeutics plans to bolster its development efforts in obesity and cardiometabolic diseases. It aims to fuse AspyreRx's clinically validated digital behavioral therapy with Click's AI-enabled platform to enhance patient care and provider capabilities. Click Therapeutics believes that its drug-software combination products can elevate patient care, improve clinical outcomes, and deliver valuable real-world data insights for providers and payers.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.